Literature DB >> 19329820

Coronary bypass surgery with or without surgical ventricular reconstruction.

Robert H Jones1, Eric J Velazquez, Robert E Michler, George Sopko, Jae K Oh, Christopher M O'Connor, James A Hill, Lorenzo Menicanti, Zygmunt Sadowski, Patrice Desvigne-Nickens, Jean-Lucien Rouleau, Kerry L Lee.   

Abstract

BACKGROUND: Surgical ventricular reconstruction is a specific procedure designed to reduce left ventricular volume in patients with heart failure caused by coronary artery disease. We conducted a trial to address the question of whether surgical ventricular reconstruction added to coronary-artery bypass grafting (CABG) would decrease the rate of death or hospitalization for cardiac causes, as compared with CABG alone.
METHODS: Between September 2002 and January 2006, a total of 1000 patients with an ejection fraction of 35% or less, coronary artery disease that was amenable to CABG, and dominant anterior left ventricular dysfunction that was amenable to surgical ventricular reconstruction were randomly assigned to undergo either CABG alone (499 patients) or CABG with surgical ventricular reconstruction (501 patients). The primary outcome was a composite of death from any cause and hospitalization for cardiac causes. The median follow-up was 48 months.
RESULTS: Surgical ventricular reconstruction reduced the end-systolic volume index by 19%, as compared with a reduction of 6% with CABG alone. Cardiac symptoms and exercise tolerance improved from baseline to a similar degree in the two study groups. However, no significant difference was observed in the primary outcome, which occurred in 292 patients (59%) who were assigned to undergo CABG alone and in 289 patients (58%) who were assigned to undergo CABG with surgical ventricular reconstruction (hazard ratio for the combined approach, 0.99; 95% confidence interval, 0.84 to 1.17; P=0.90).
CONCLUSIONS: Adding surgical ventricular reconstruction to CABG reduced the left ventricular volume, as compared with CABG alone. However, this anatomical change was not associated with a greater improvement in symptoms or exercise tolerance or with a reduction in the rate of death or hospitalization for cardiac causes. (ClinicalTrials.gov number, NCT00023595.) 2009 Massachusetts Medical Society

Entities:  

Mesh:

Year:  2009        PMID: 19329820      PMCID: PMC3265934          DOI: 10.1056/NEJMoa0900559

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  19 in total

1.  ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).

Authors:  Kim A Eagle; Robert A Guyton; Ravin Davidoff; Fred H Edwards; Gordon A Ewy; Timothy J Gardner; James C Hart; Howard C Herrmann; L David Hillis; Adolph M Hutter; Bruce Whitney Lytle; Robert A Marlow; William C Nugent; Thomas A Orszulak
Journal:  Circulation       Date:  2004-10-05       Impact factor: 29.690

2.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction.

Authors:  M A Pfeffer; G A Lamas; D E Vaughan; A F Parisi; E Braunwald
Journal:  N Engl J Med       Date:  1988-07-14       Impact factor: 91.245

3.  Prognostic value of radionuclide angiography in medically treated patients with coronary artery disease. A comparison with clinical and catheterization variables.

Authors:  K L Lee; D B Pryor; K S Pieper; F E Harrell; R M Califf; D B Mark; M A Hlatky; R E Coleman; F R Cobb; R H Jones
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

4.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

5.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society.

Authors:  Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2005-09-13       Impact factor: 29.690

6.  Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.

Authors:  R N Doughty; G A Whalley; G Gamble; S MacMahon; N Sharpe
Journal:  J Am Coll Cardiol       Date:  1997-04       Impact factor: 24.094

Review 7.  Surgical methods to reverse left ventricular remodeling in congestive heart failure.

Authors:  Ottavio Alfieri; Francesco Maisano; Jan J Schreuder
Journal:  Am J Cardiol       Date:  2003-05-08       Impact factor: 2.778

8.  Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation.

Authors:  Constantine L Athanasuleas; Gerald D Buckberg; Alfred W H Stanley; William Siler; Vincent Dor; Marisa Di Donato; Lorenzo Menicanti; Sergio Almeida de Oliveira; Friedhelm Beyersdorf; Irving L Kron; Hisayoshi Suma; Nicholas T Kouchoukos; Wistar Moore; Patrick M McCarthy; Mehmet C Oz; Francis Fontan; Meredith L Scott; Kevin A Accola
Journal:  J Am Coll Cardiol       Date:  2004-10-06       Impact factor: 24.094

9.  Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy.

Authors:  Robert N Doughty; Gillian A Whalley; Helen A Walsh; Greg D Gamble; José López-Sendón; Norman Sharpe
Journal:  Circulation       Date:  2004-01-05       Impact factor: 29.690

10.  Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy.

Authors:  B Greenberg; M A Quinones; C Koilpillai; M Limacher; D Shindler; C Benedict; B Shelton
Journal:  Circulation       Date:  1995-05-15       Impact factor: 29.690

View more
  135 in total

Review 1.  Surgical approach to mitral regurgitation in chronic heart failure: when is it an option?

Authors:  Juan A Crestanello
Journal:  Curr Heart Fail Rep       Date:  2012-03

Review 2.  Reverse remodeling in heart failure--mechanisms and therapeutic opportunities.

Authors:  Norimichi Koitabashi; David A Kass
Journal:  Nat Rev Cardiol       Date:  2011-12-06       Impact factor: 32.419

Review 3.  Embryonic stem cells for severe heart failure: why and how?

Authors:  Philippe Menasché
Journal:  J Cardiovasc Transl Res       Date:  2012-03-13       Impact factor: 4.132

4.  Impact of surgical ventricular reconstruction for ischemic dilated cardiomyopathy on restrictive filling pattern.

Authors:  Yasuhiro Shudo; Goro Matsumiya; Taichi Sakaguchi; Shigeru Miyagawa; Takashi Yamauchi; Koji Takeda; Shunsuke Saito; Kazuhiro Taniguchi; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-08-12

5.  General overview of the Sixth International Symposium on Stem Cell Therapy and Cardiovascular Innovations.

Authors:  Ma Eugenia Vázquez-Alvarez; Ricardo Sanz-Ruiz; Enrique Gutiérrez; Adolfo Villa; Ma Eugenia Fernández; Sandra Vázquez; Ma José Lorenzo; Lucía Fernández; Isaac Pascual; Pedro L Sánchez; Francisco Fernández-Avilés
Journal:  J Cardiovasc Transl Res       Date:  2009-12-10       Impact factor: 4.132

6.  Growth and remodeling of the left ventricle: A case study of myocardial infarction and surgical ventricular restoration.

Authors:  Doron Klepach; Lik Chuan Lee; Jonathan F Wenk; Mark B Ratcliffe; Tarek I Zohdi; Jose A Navia; Ghassan S Kassab; Ellen Kuhl; Julius M Guccione
Journal:  Mech Res Commun       Date:  2012-03-12       Impact factor: 2.254

7.  Myocardial viability and impact of surgical ventricular reconstruction on outcomes of patients with severe left ventricular dysfunction undergoing coronary artery bypass surgery: results of the Surgical Treatment for Ischemic Heart Failure trial.

Authors:  Thomas A Holly; Robert O Bonow; J Malcolm O Arnold; Jae K Oh; Padmini Varadarajan; Gerald M Pohost; Haissam Haddad; Robert H Jones; Eric J Velazquez; Bozena Birkenfeld; Federico M Asch; Marcin Malinowski; Rodrigo Barretto; Renato A K Kalil; Daniel S Berman; Jie-Lena Sun; Kerry L Lee; Julio A Panza
Journal:  J Thorac Cardiovasc Surg       Date:  2014-07-30       Impact factor: 5.209

Review 8.  Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system.

Authors:  P Boekstegers; J Hausleiter; S Baldus; R S von Bardeleben; H Beucher; C Butter; O Franzen; R Hoffmann; H Ince; K H Kuck; V Rudolph; U Schäfer; W Schillinger; N Wunderlich
Journal:  Clin Res Cardiol       Date:  2014-02       Impact factor: 5.460

9.  Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials.

Authors:  Arthur M Feldman; Douglas L Mann; Lilin She; Michael R Bristow; Alan S Maisel; Dennis M McNamara; Ryan Walsh; Dorellyn L Lee; Stanislaw Wos; Irene Lang; Gretchen Wells; Mark H Drazner; John F Schmedtje; Daniel F Pauly; Carla A Sueta; Michael Di Maio; Irving L Kron; Eric J Velazquez; Kerry L Lee
Journal:  Circ Heart Fail       Date:  2013-04-12       Impact factor: 8.790

10.  Comparative effectiveness and health care spending--implications for reform.

Authors:  Milton C Weinstein; Jonathan A Skinner
Journal:  N Engl J Med       Date:  2010-01-06       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.